(11)C-metomidate PET-CT is a sensitive and specific noninvasive alternative to AVS in the management of PHA.

Several tumour biological variables not included in the seventh edition of the AJCC classification affect overall survival. These require incorporation into prognostic models to ensure a personalized approach to prognostication and treatment.

Expression of hENT1 is a suitable prognostic biomarker in patients undergoing adjuvant gemcitabine-based chemotherapy.

No abstract

Current imaging techniques for detecting bone metastases in renal carcinoma are insensitive to small lesions. This prospective trial of 18F-NaF PET/CT shows it is more than twice as sensitive as CT and more than three times as sensitive as bone scintigraphy for these lesions. 18F-NaF PET/CT could alter management by identifying occult metastases in patients with negative standard-of-care imaging.